Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study
Clinical Pharmacology & Therapeutics · 2023-10 · 114 (4) · 883-892
DOI: 10.1002/cpt.2994 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 19.07.2023. Verfasst von Ruben P A van Eijk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Data Science and Centre for Innovative Study Design, School of Medicine, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hybrid designs with both randomized arms and an external control cohort preserve key features of randomization and utilize external information to augment clinical trials. In this study, we propose to leverage high‐quality, patient‐level concurrent registries to enhance clinical trials and illustrate the impact on trial design for amyotrophic lateral sclerosis. The proposed methodology was evaluated in a randomized, placebo‐controlled clinical trial. We used patient‐level information from a well‐defined, population‐based registry, that was running parallel to the randomized clinical trial, to identify concurrently nonparticipating, eligible patients who could be matched with trial participants, and integrate them into the statistical analysis. We assessed the impact of the addition of the external controls on the treatment effect estimate, precision, and time to reach a conclusion. During the runtime of the trial, a total of 1,141 registry patients were alive; 473 (41.5%) of them fulfilled the eligibility criteria and 133 (11.7%) were enrolled in the study. A matched control population could be identified among the nonparticipating patients. Augmenting the randomized controls with matched external controls could have avoided unnecessary randomization of 17 patients (−12.8%) as well as reducing the study duration from 30.1 months to 22.6 months (−25.0%). Matching eligible external controls from a different calendar period led to bias in the treatment effect estimate. Hybrid trial designs utilizing a concurrent registry with rigorous matching can minimize bias due to a mismatch in calendar time and differences in standard of care, and may accelerate the development of new treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Biomedical Data Science and Centre for Innovative Study Design, School of Medicine, Stanford University, Stanford, California, USA.
- Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Section Biostatistics, Department of Health Evidence, Radboud Medical Centre, Nijmegen, The Netherlands.
- Department of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, California, USA.
- UCB Pharma, Brussels, Belgium.
ORCID-Profile: Ruben P A van Eijk, Leonard H van den Berg, Kit C B Roes, Lu Tian, Lorene M Nelson, Anna Scowcroft, Ying Lu
Zitieren
APA
van Eijk, R. P. A., van den Berg, L. H., Roes, K. C. B., Tian, L., Lai, T. L., Nelson, L. M., Li, C., Scowcroft, A., Garcia-Segovia, J., & Lu, Y. (2023). Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study. Clinical Pharmacology & Therapeutics, 114(4), 883-892. https://doi.org/10.1002/cpt.2994
Vancouver
van Eijk RPA, van den Berg LH, Roes KCB, Tian L, Lai TL, Nelson LM, et al. Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study. Clinical Pharmacology & Therapeutics. 2023;114(4):883-892. doi:10.1002/cpt.2994
BibTeX
@article{vanEijk2023,
author = {van Eijk, Ruben P A and van den Berg, Leonard H and Roes, Kit C B and Tian, Lu and Lai, Tze L and Nelson, Lorene M and Li, Chenyu and Scowcroft, Anna and Garcia-Segovia, Jesus and Lu, Ying},
title = {Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {114},
number = {4},
pages = {883--892},
doi = {10.1002/cpt.2994}
}
EUVIMED